Spore-ing change: Rua Bioscience psilocybin study targets meth addiction

Spore-ing change: Rua Bioscience psilocybin study targets meth addiction
Gisborne-based pharmaceutical company Rua Bioscience is hoping mushrooms can help cure meth addiction. (Image: Supplied)
Gregor Thompson
Rua Bioscience is exploring psilocybin-containing mushrooms’ potential in treating methamphetamine addiction.The clinical study, dubbed Tū Wairua (standing with strength and spiritual connectedness), intends to combine historic Māori practices with modern science to tackle meth addiction.The New Zealand Exchange-listed (NZX) and the Gisborne-based medical cannabis company announced Phase I of the new trial on Tuesday.“Over the past week, the first cohort of marae-based participants engaged in preparatory and experiential sessio...

More Markets

NZ sharemarket edges higher as F&P Healthcare weighs on gains
Markets Market Close

NZ sharemarket edges higher as F&P Healthcare weighs on gains

The S&P/NZX 50 Index closed 14.49 points or 0.11% down at 13,391.59.

Contact Energy expands global investor base
Markets

Contact Energy expands global investor base

Contact Energy priced an inaugural €500 million (NZ$1.01b) 7-year senior bond under its Euro Medium Term Note (EMTN) Programme, it said Friday.“This marks a milestone in Contact’s funding strategy, expanding our global investor base and reinforcing our commitment to sustainable f...

Kiwibank wary of capital-review barrier to growth
Finance

Kiwibank wary of capital-review barrier to growth

Kiwibank raises issues of competitive advantage.

Fonterra windfall brings risks: ASB
Primary Sector

Fonterra windfall brings risks: ASB

Farmers will vote for the Lactalis deal on Oct 30.